![Julie Hambleton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julie Hambleton
Directeur/Bestuurslid bij
ERASCA, INC.
Vermogen: 77 040 $ op 31-05-2026
Profiel
Julie Hambleton is currently an Independent Director at Erasca, Inc. since 2021, Onc.ai, Inc., and Gennao Bio, Inc. since 2021.
Formerly, Dr. Hambleton was President, Chief Executive Officer & Director at Arch Oncology, Inc. from 2020 to 2021; Director at Accent Therapeutics, Inc. from 2020 to 2021; Independent Director at IGM Biosciences, Inc. from 2018 to 2025; Independent Director at Springworks Therapeutics, Inc. from 2020 to 2025; Vice President & Head-US Medical at Bristol Myers Squibb Co. from 2016 to 2017; Chief Medical Officer & Executive Vice President at Five Prime Therapeutics, Inc. from 2015 to 2016; Associate Professor at The University of California, San Francisco from 1993 to 2003; Vice President-Clinical Development at Clovis Oncology, Inc. from 2010 to 2012; Chief Medical Officer, SVP & Head-Development at IDEAYA Biosciences, Inc. from 2018 to 2020; and Medical Director-Global Clinical Development at Genentech, Inc. from 2003 to 2010.
Education includes undergraduate studies at Duke University and a doctorate from Case Western Reserve University School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 26-06-2026 | 6.000 ( 0% ) | 77 040 $ | 31-05-2026 |
Actieve functies van Julie Hambleton
| Bedrijven | Functie | Begin |
|---|---|---|
| ERASCA, INC. | Directeur/Bestuurslid | 29-03-2021 |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted nucleic acid therapeutics to cure muscle diseases | Directeur/Bestuurslid | 13-07-2021 |
Onc.ai, Inc.
 Onc.ai, Inc. Packaged SoftwareTechnology Services Develops precision oncology care management platform that aims to transform clinical decision making | Directeur/Bestuurslid | - |
Eerdere bekende functies van Julie Hambleton
| Bedrijven | Functie | Einde |
|---|---|---|
| IGM BIOSCIENCES, INC. | Directeur/Bestuurslid | 14-08-2025 |
| SPRINGWORKS THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-07-2025 |
Arch Oncology, Inc.
 Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Algemeen Directeur | 01-04-2021 |
Accent Therapeutics, Inc.
 Accent Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops treatments for cancer patients | Directeur/Bestuurslid | 01-03-2021 |
| IDEAYA BIOSCIENCES, INC. | Hoofd Techniek/Wetenschap/O&O | 30-04-2020 |
Opleiding van Julie Hambleton
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
86
Eerstegraads connecties
15
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 15 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as an biopharmaceutical company that acquires, develops and commercializes innovative anti cancer agents | Health Technology |
Arch Oncology, Inc.
Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Health Technology |
Case Western Reserve University School of Medicine
 Case Western Reserve University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IDEAYA Biosciences, Inc.
 IDEAYA Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as oncology-focused precision medicine company which develops and sells cancer therapeutics | Health Technology |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
Accent Therapeutics, Inc.
Accent Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops treatments for cancer patients | Health Technology |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Springworks Therapeutics, Inc.
 Springworks Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes medicines for nervous system disorders | Health Technology |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Develops precision oncology care management platform that aims to transform clinical decision making | Technology Services |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted nucleic acid therapeutics to cure muscle diseases | Health Technology |
Kies MarketScreener 
